reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

Apimeds Pharmaceuticals US, Inc.

APUS · NYSE

2 reporting failures in the last 12 months

Companies at this level ended the following year delisted, bankrupt, restated or silent 13.1% of the time, against 4.0% for companies with a clean record.

$8Mpublic float
2026-05-15most recent failure

Score over time

0123202520262025-04-01 · score 12025-03-31 filed late (10-K) · accounts not ready2025-07-01 · score 22025-05-15 filed late (10-Q) · accounts not ready2025-03-31 filed late (10-K) · accounts not ready2025-10-01 · score 32025-08-14 filed late (10-Q) · accounts not ready2025-05-15 filed late (10-Q) · accounts not ready2025-03-31 filed late (10-K) · accounts not ready2026-01-01 · score 32025-08-14 filed late (10-Q) · accounts not ready2025-05-15 filed late (10-Q) · accounts not ready2025-03-31 filed late (10-K) · accounts not ready2026-04-01 · score 32026-03-31 filed late (10-K) · auditor2025-08-14 filed late (10-Q) · accounts not ready2025-05-15 filed late (10-Q) · accounts not ready2026-07-01 · score 32026-05-15 filed late (10-Q) · accounts not ready2026-03-31 filed late (10-K) · auditor2025-08-14 filed late (10-Q) · accounts not ready2026-10-01 · score 22026-05-15 filed late (10-Q) · accounts not ready2026-03-31 filed late (10-K) · auditor

Hover or tap a dot to see the filings behind that score.

Why they said they were late

Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 (the “ Form 10-Q ”) by the prescribed due date because the Company is in the process of finalizing the financial statements for the fiscal quarter ended March 31, 2026, and will need additional time to complete such financial statements. The Company anticipates that it will file the Form 10-Q within the extension period of five calendar days as provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended

NT 10-Q, filed 2026-05-15 · accounts not ready

What it filed

2026-05-15filed late (10-Q)accounts not ready SEC →

Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 (the “ Form 10-Q ”) by the prescribed due date because the Company is in the process of finalizing the financial statements for the fiscal quarter ended March 31, 2026, and will need additional time to complete such financial statements. The Company anticipates that it will file the Form 10-Q within the extension period of five calendar days as provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended

2026-03-31filed late (10-K)auditor SEC →

Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”) has determined that it is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fourth quarter and fiscal year ended December 31, 2025 (the “ 2025 Form 10-K ”) by the prescribed due date because the Company is in the process of preparing the financial statements for the fourth quarter and fiscal year ended December 31, 2025, and will need additional time to complete such financial statements. The Company’s independent registered public accounting firm will also need additional time to complete its review and audit of the financial statements for the fourth quarter and fiscal year ended December 31, 2025. The Company anticipates that it will file its 2025 Form 10-K within the fifteen-day grace period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended

2025-08-14filed late (10-Q)accounts not ready SEC →

Apimeds Pharmaceuticals US, Inc. (the “ Company ”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025 (the “ Form 10-Q ”) by the prescribed due date because the Company is in the process of finalizing the financial statements for the quarter ended June 30, 2025 and will need additional time to complete and finalize such financial statements. The Company anticipates that it will file its Form 10-Q within the five-day extension period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended

2025-05-15filed late (10-Q)accounts not ready SEC →

Apimeds Pharmaceuticals US, Inc. (the “ Company ”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 (the “ Form 10-Q ”) by the prescribed due date because the Company is in the process of finalizing the financial statements for the quarter ended March 31, 2025 and will need additional time to complete and finalize such financial statements. The Company anticipates that it will file its Form 10-Q within the five-day extension period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended

2025-03-31filed late (10-K)accounts not ready SEC →

Apimeds Pharmaceuticals US, Inc. (the “ Company ”) has determined that it is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “ Form 10-K ”) by the prescribed due date because the Company is in the process of preparing the financial statements for the year ended December 31, 2024 and will need additional time to complete such financial statements. The Company anticipates that it will file its Form 10-K within the fifteen-day extension period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com